Initiator Pharma A/S

Stockholm Stock Exchange INIT.ST

Initiator Pharma A/S Price to Earnings Ratio (P/E) on January 14, 2025: -10,641.44

Initiator Pharma A/S Price to Earnings Ratio (P/E) is -10,641.44 on January 14, 2025, a 21.29% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Initiator Pharma A/S 52-week high Price to Earnings Ratio (P/E) is -9,650.65 on November 22, 2024, which is 9.31% above the current Price to Earnings Ratio (P/E).
Initiator Pharma A/S 52-week low Price to Earnings Ratio (P/E) is -15,487.92 on June 12, 2024, which is -45.54% below the current Price to Earnings Ratio (P/E).
Initiator Pharma A/S average Price to Earnings Ratio (P/E) for the last 52 weeks is -12,373.76.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

Stockholm Stock Exchange: INIT.ST

Initiator Pharma A/S

CEO	Dr. Claus Elsborg Olesen
IPO Date	March 16, 2017
Location	Denmark
Headquarters	Ole Maaloes vej 3
Employees	3
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. It develops IP2018, a monoamine reuptake inhibitor for the treatment of psychogenic erectile dysfunction; IPED2015 to treat patients suffering from organic erectile dysfunction; and IPTN2021 for targeting an orphan drug indication in severe neuropathic pain. The company's pre-clinical stage candidates include IPNP2015 for the treatment of chronic pain; and IPDP2015 for depression. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark.

Key trends

Past 5 years